A collaboration with the Roche pharmaceutical company led to the screening of 200 000 Roche compounds
on human neural stem cells in order to identify proliferative drugs.
Not exact matches
Thus,
neural derivatives of disease - specific
human pluripotent
stem cells constitute a relevant biological resource for exploring the impact of adult - onset HD mutations of the HTT gene
on the division of
neural progenitors, with potential applications in HD drug discovery targeting HTT - dynein - p150Glued complex interactions.
Dr. Sonntag studies this concept
on the molecular and cellular level using a translational research approach that integrates the analysis of
human material, such as postmortem brains, primary
cell systems, and
neural cell populations generated from patients» - or healthy individuals» - derived induced pluripotent
stem cells (iPSC), or induced neurons (iNs), in combination with molecular, biochemistry, and lentivirus - mediated gene - engineering technologies.
The group's objectives are focused
on using
neural progenies of
human Pluripotent
Stem (hPS)
cells to understand and develop new treatments for Huntington Disease (HD).
NeuroStemcell is focused
on the identification and systematic comparison of progenitor
cell lines with the most favourable characteristics for mesDA and striatal GABAergic neuronal differentiation, generated either directly from
human embryonic
stem (ES) cells, from Neural Stem (NS) cells derived from ES cells or fetal brain, from induced Pluripotent Stem (iPS) cells or from in vitro short - term expanded neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals mod
stem (ES)
cells, from
Neural Stem (NS) cells derived from ES cells or fetal brain, from induced Pluripotent Stem (iPS) cells or from in vitro short - term expanded neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals m
Neural Stem (NS) cells derived from ES cells or fetal brain, from induced Pluripotent Stem (iPS) cells or from in vitro short - term expanded neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals mod
Stem (NS)
cells derived from ES
cells or fetal brain, from induced Pluripotent
Stem (iPS) cells or from in vitro short - term expanded neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals mod
Stem (iPS)
cells or from in vitro short - term expanded
neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate cells in appropriate animals m
neural progenitors from ventral midbrain grown as neurospheres (VMN, Ventral Midbrain Neurospheres) 4, and perform rigorous and systematic testing of the most prominent candidate
cells in appropriate animals models.
Russell Kern reports
on the 6 - month update
on the first - in -
human clinical study of
neural stem cells in patients with Parkinson's disease.
The team used genetically engineered mice to study the effects of different
human apoE variants
on the maturation of
neural stem cells or progenitor
cells, from which new neurons develop in the adult brain.
Applying these paradigms
on various
neural differentiation schemes of
human pluripotent
stem cells allows us to identify and isolate new types of
neural stem and progenitor
cells, to characterize their cellular properties and molecular foundations, to expose their progenitor origin and track their imminent potential, to reveal their in vivo counterparts and learn about their regenerative potential.
While previous studies had demonstrated a synergistic effect of BMP and LIF
on the astrocytic differentiation of
human neural stem cells [15], it remains unclear whether BMP and LIF induce distinct types of astrocytes and if so, what the functional properties of these astrocytes may be with respect to repairing CNS injuries.
The
human NSCs have a typical, undifferentiated
neural stem cell morphology when expanding as monolayers
on laminin - coated plates (Fig. 1A).
They went
on to show that Sox10, a factor needed for the formation of skin pigment
cells from
neural crest
stem cells during development, was present at high levels in naevi and melanoma samples obtained from both the mouse model and
human patients.
On the other hand, ES
cells and
cells differentiating into endoderm and mesoderm lineages from ES
cells express OCT - 4 in mice and
humans [66], and SSEA1 expression is found in other type of
cells including
neural stem cells and mesenchymal
stem cells [67], [68].
Our initial studies were
on characterization of different adult
neural stem cell types from murine and
human brain and
human bone marrow.